Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07557303 · ClinicalTrials.gov registry record · NA
Supporting Just-In-Time Consent for Prenatal Screening: The INFORM Study
A NA study, sponsored by Case Western Reserve University.
- Not yet
- Registry status
- NA
- Development phase
- 1,400
- Enrollment target
NCT07557303: Clinical Trial NA study, sponsored by Case Western Reserve University.
NCT07557303 is a NA study that has not yet begun recruiting, run by Case Western Reserve University. The registered enrollment target is 1,400 participants, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07557303, a NA study, has not yet begun recruiting, sponsored by Case Western Reserve University.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 1,400 participants
- Enrollment target
Study Summary
This clinical trial is about prenatal genetic screening. It will test an intervention to help people make decisions about screening. The intervention is a short set of information cards about screening. This intervention is for pregnant participants. They will use the intervention on their mobile phone before they see their doctor. The study has one main question: * Do participants who use the intervention feel more confident when they make a decision about screening? Researchers will compare participants who use the intervention to participants who do not. All participants will have their usual care when they visit their doctor. What will participants do? * Participants must be pregnant. They will sign up for the study before their first doctor's visit for their pregnancy. This is the visit where their doctor usually talks with them about screening. * Some participants will use the intervention before their first doctor's visit. Other participants will not use it. * All participants will talk with a researcher on the phone after their first doctor's visit. * Participants who use the intervention will answer a short survey on their phone. * A few participants who use the intervention will talk with a researcher a second time on the phone.
Primary Outcome
Decision self-efficacy is measured using a slightly adapted version of the "Decision Self-Efficacy Scale" developed by A. O'Connor and colleagues at the Ottawa Hospital Research Institute and is available at https://decisionaid.ohri.ca. The scale contains eleven questions about a patient's decision-making process. The scale was adapted to ask questions about the context of prenatal genetic screening and utilizes a three-point response scale. Response choices and corresponding point values are: "
Interventions
- BEHAVIORAL Mobile-based Educational Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,400 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2028-06-30 |
| Phase | NA |
What is known before NCT07557303 opens enrollment
NCT07557303 is an interventional study that assigns participants to a tested intervention. Its 1,400 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Mobile-based Educational Intervention is the first listed.
NCT07557303 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07557303 about?
NCT07557303 is a clinical study titled "Supporting Just-In-Time Consent for Prenatal Screening: The INFORM Study". This clinical trial is about prenatal genetic screening. It will test an intervention to help people make decisions about screening. The intervention is a short set of information cards about screening. This intervention is for pregnant participants. They will use the intervention on their mobile ph...
What is the current status of trial NCT07557303?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 1,400 participants. The study started on 2026-08-01. Estimated completion is 2028-06-30.
What interventions are being tested in trial NCT07557303?
The interventions under investigation include: Mobile-based Educational Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT07557303?
This trial is sponsored by Case Western Reserve University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07557303's enrollment target sits among peer trials
1,400 71st of 2000 higher than 1,928 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02205762 · 1,400 participants · Phase 2
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
- NCT02445222 · 1,400 participants · Phase 3
CAR-T Long Term Follow Up (LTFU) Study
- NCT03145077 · 1,400 participants · NA
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body
- NCT04250857 · 1,400 participants
HeartStart FRx Defibrillator Event Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI